美股新聞 標題聯播 · 近 24 小時 336 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · ORIC近 30 天 3 則 · 第 1 / 1 頁
- ORIC (ORIC) Doubles Down On Prostate Cancer With Phase 3 Launch
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
- Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
- ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
- ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
- ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
- Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
- ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
- ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
- A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
- ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
- Oric Pharma Misses The 'Best-In-Class' Boat Vs. Pfizer — And Plunges
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。